TP53 and sarcoma: As this drug inhibits SIRT1 from deacetylating p53 at K382 in several tumor cells stabilizing p53 expression and reactivating its apoptotic function,4, 5, 6 we hypothesized that acetylation of K382-p53 could be as well compromised in Tv6-treated sarcoma cells; however, we found that the antiproliferative effect of Tv6 was independent of the p53 gene status (wild type or mutated), K382-p53 acetylation or apoptotic function.